Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Pentazocine lactate [USAN]
RN: 17146-95-1
UNII: 1P2XIB510O
InChIKey: QNLDTXPVZPRSAM-NMVCJIEOSA-N

Note

  • Pentazocine. The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)

Molecular Formula

  • C19-H27-N-O.C3-H6-O3

Molecular Weight

  • 375.5057
 

Classification Codes

  • Analgesic
  • Human Data
* denotes mobile formatted website

Links to Resources


Search for this InChIKey on the Web

Names and Synonyms

Name of Substance

  • Pentazocine lactate [USAN]

Synonyms

  • (2R*,6R*,11R*)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol lactate (salt)
  • 2-Hydroxypropanoic acid compd. with (2alpha,6alpha,11R*)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methanol-3-benzocin-8-ol (1:1)
  • EINECS 241-209-9
  • EINECS 304-943-1
  • Liticon
  • Pentalgine
  • Pentazocine lactate
  • Talwin
  • Talwin (as lactate)
  • Talwin Injection
  • UNII-1P2XIB510O

Systematic Names

  • 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2alpha,6alpha,11R*)-, compd. with 2-hydroxypropanoic acid (1:1)
  • Lactic acid, compd. with 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol (1:1)
  • Lactic acid, compound with (2alpha,6alpha,11R*)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzocin-8-ol (1:1)
  • Propanoic acid, 2-hydroxy-, compd. with (2alpha,6alpha,11R*)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methanol-3-benzocin-8-ol (1:1)

Registry Numbers

CAS Registry Number

  • 17146-95-1

FDA UNII

  • 1P2XIB510O

Other Registry Numbers

  • 22242-36-0
  • 22242-37-1
  • 94293-50-2

Related Registry Number

  • 359-83-1 (Parent)

System Generated Number

  • 0017146951

Molecular Formulas

Molecular Formula

  • C19-H27-N-O.C3-H6-O3

Molecular Formula Fragments

  • C19-H27-N-O
  • C3-H6-O3
  • COMPONENT

Structure Descriptors

InChI

1S/C19H27NO.C3H6O3/c1-13(2)7-9-20-10-8-19(4)14(3)18(20)11-15-5-6-16(21)12-17(15)19;1-2(4)3(5)6/h5-7,12,14,18,21H,8-11H2,1-4H3;2,4H,1H3,(H,5,6)/t14-,18+,19+;/m1./s1

InChIKey

QNLDTXPVZPRSAM-NMVCJIEOSA-N

Smiles

CC(O)C(=O)O.C[C@@H]1[C@@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C(C)C

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
man TDLo parenteral 16mg/kg/3W-I (16mg/kg) MUSCULOSKELETAL: OTHER CHANGES Journal of Rheumatology. Vol. 13, Pg. 210, 1986.
mouse LD50 intraperitoneal 103mg/kg (103mg/kg)   Journal of Pharmacy and Pharmacology. Vol. 23, Pg. 882, 1971.
women TDLo subcutaneous 2mg/kg (2mg/kg) SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" Archives of Dermatology. Vol. 123, Pg. 297, 1987.